

February 3-5, 2026 | La Jolla, San Diego, CA

www.lbx-summit.com

FREE TO ATTEND
FOR BIOTECH &
PHARMA*



10TH ANNIVERSARY

Liquid Biopsy for Precision Oncology Summit

Transforming Precision Therapies Through Robust Liquid Biopsy Testing

Address Translational & Commercial Challenges to Seamlessly Utilize Liquid Biopsy Technologies to Drive Smarter, Accelerated Oncology Drug Development

Expert Speakers Include:



Ildiko Csiki
Chief Medical Officer
**Geneos
Therapeutics**



Claudia Dollins
Vice President,
Global Regulatory
Affairs
GSK



Michelle Neff
Associate Vice
President, Global
Regulatory Affairs,
Diagnostics
Eli Lilly



Oliver Rosen
Chief Medical Officer
Akamis Bio



Jennifer Hamilton
Vice President,
Precision Medicine
Regeneron



Steffan Ho
Vice President,
Translational
Oncology
Pfizer

Proud to Partner With:



**FOUNDATION
MEDICINE**



GUARDANT



natera

TEMPUS



+1 617 455 4188



info@hansonwade.com



www.lbx-summit.com



Biomarkers & Companion Diagnostics



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Celebrating a Decade of the Liquid Biopsy for Precision Oncology Summit

 **10** Liquid Biopsy for Precision Oncology Summit

February 3-5, 2026
La Jolla, San Diego, CA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Liquid biopsies are empowering biopharma leaders to identify actionable mutations, dynamically monitor therapeutic response, and detect minimal residual disease with unparalleled sensitivity. These capabilities are dramatically improving clinical trial efficiency and therapeutic precision; however, alongside this opportunity lies the challenge of embedding liquid biopsies into development workflows that satisfy regulatory requirements, generate payer-relevant evidence, and deliver proven clinical utility.

Celebrating its **10th anniversary**, the **Liquid Biopsy for Precision Oncology Summit** brings together biopharma, diagnostic developers, clinical providers, payers, and regulators with a shared goal: to align on actionable strategies that accelerate the development and adoption of liquid-based biomarkers, driving smarter, faster, and more scalable oncology drug development.

Join **250+** leading minds in **Precision Medicine**, **Translational Science** and **Diagnostics** to gain the insights and partners you require to enable more confident decision-making at every stage of development – ensuring timely, accessible and affordable precision oncology treatments for unmet patient needs.

Regardless of your therapeutic indication or modality, if you need deeper insights into patient stratification, more effective monitoring, earlier detection of relapse, or validation of surrogate endpoints, this is your opportunity to:

- **Accelerate clinical development timelines** by embedding liquid biopsy into adaptive trial design for patient stratification, early efficacy assessment and MRD surveillance
- **Enhance translational strategy** with emerging ctDNA, CTC, and multi-omic biomarkers tailored to your modality and indication
- **Navigate evolving regulatory expectations** for biomarker-driven development and companion diagnostic alignment
- **Strengthen reimbursement and commercialization pathways** by generating data that resonates with payers and supports real-world value
- **Establish strategic collaborations** with diagnostics developers and CROs to de-risk development and scale implementation

Key Benefits of Attending



Leverage emerging analytes and cutting-edge technologies to optimize ctDNA integration for dose-finding and pharmacodynamic studies to minimize patient over-treatment, with insights from:



Genentech



Unleash deeper resolution into patient and tumor heterogeneity with next-generation methylation profiling to refine stratification and predictive biomarker strategies to prevent costly late-stage trial failures, with exciting data from:



AstraZeneca



Expedite global clinical trials by harmonizing regulatory pathways for liquid biopsy use to reduce delays and uncertainty, accelerate approvals, and reach patients faster, with key strategies by:

GSK

Bristol Myers Squibb



Refine the validation of MRD as a surrogate endpoint, paving the way for expanded approvals in hematologic malignancies and a first solid tumor indication to transform cancer treatment, explored by:

REGENERON

AKAMIS BIO



Discover the expanding frontiers of liquid biopsy as blood-based biomarkers reshape early detection and monitoring in broader disease applications, unlocking novel therapeutic avenues, discussed by:

AMGEN


Lilly



10 Years of Progress, One Defining Mission

From a room of pioneers in 2016, to what is now a global community, the rate of progress and innovation in liquid biopsies is unparalleled. Now, after a decade fuelled with investments, partnerships, collaborations and clinical impact, the **10th Liquid Biopsy for Precision Oncology Summit** is uniting the field to realize its full potential.

Take a look at the milestones this community has hit in just 10 years:



Whilst it is critical to reflect on the progress we have made, it is even more important to set goals for the future ahead that can ensure liquid biopsies reach every patient subtype.

This year, our mission is clear:

01

Accelerate Clinical Adoption:
Build consensus on validation, regulatory, and reimbursement strategies to embed liquid biopsy into routine oncology care.

02

Drive Standardization:
Establish common frameworks for assays, data, and workflows to ensure robust, reproducible, and clinically meaningful results across the field.

03

Ensure Global Equity & Access:
Champion diverse patient representation, scalable technologies, and international harmonization so that every patient, everywhere, can benefit from liquid biopsy.

Together, we have the opportunity to transform liquid biopsy from promise to practice, and from innovation to impact, shaping a future where precision oncology is accessible to all.

Join us in 2026 at the world's largest industry gathering for experts in liquid biopsy, and shape the future of precision medicine, today.

Your Expert Speakers

 **10** Liquid Biopsy for Precision Oncology Summit

February 3-5, 2026
La Jolla, San Diego, CA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Pharma Giants



Amrita Pati
Executive Director of
Computational Biology,
Precision Medicine
Amgen



Leo Grimaldi
Senior Director, Head of
Strategy & Operations,
Precision Medicine
Amgen



Cedric Dos Santos
Global Product Leader
AstraZeneca



Jonathan Baden
Executive Director & Head,
Precision Medicine
Bristol Myers Squibb



Michelle Neff
Associate Vice President,
Global Regulatory Affairs,
Diagnostics & Companion
Diagnostics
Eli Lilly



Yanwen Jiang
Distinguished Scientist
Genentech



Claudia Dollins
Vice President, Global
Regulatory Affairs
GSK



David Weingeist
Scientific Director,
Oncology Diagnostics
Leader
Johnson & Johnson



Partha Das
Global Medical Director -
Precision Medicine
Johnson & Johnson



Fernando Cruz-Guilloty
Director - Oncology
Precision Medicine & Lung
Franchise Lead
Johnson & Johnson



Cynthia Sandoval
Senior Director, Clinical
Biomarker Development
Eli Lilly



Steffan Ho
Vice President,
Translational Oncology
Pfizer



Jennifer Hamilton
Vice President, Precision
Medicine
Regeneron

Innovative Biotech



Oliver Rosen
Chief Medical Officer
Akamis Bio



Joan Chen
Executive Director,
Bioinformatics
Boundless Bio



Hua Gong
Vice President,
Translational Medicine
**BBOT (BridgeBio
Oncology Therapeutics)**



Ildiko Csiki
Chief Medical Officer
Geneos Therapeutics



Anneleen Daemen
Executive Director,
Translational Medicine
Oric Pharmaceuticals



Zoe June Assaf
Senior Director, Cancer
Genomics & Emerging
Technologies
Revolution Medicines



Amer Mirza
Vice President, Disease
Biology & Translational
Sciences
Septerna



Jelveh Lameh
Head, Translational
Research
Zai Laboratory

Your Expert Speakers

10th Liquid Biopsy for Precision Oncology Summit

February 3-5, 2026
La Jolla, San Diego, CA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Leading Voices



Lauren Leiman
Executive Director
BLOODPAC



Hadly Clark
Director
**FasterCures, Milken
Institute**



Anjee Davis
Chief Executive Officer
Fight CRC



Daad Abighanem
Cancer Patient/Survivor
Fight CRC



Anthony Chi
Medical Director
Kaiser Permanente



Daniel Kim
Assistant Professor & Co-
Chair
**UC Santa Cruz & NIH
Liquid Biopsy Scientific
Interest Group**



Hatim Husain
Professor of Medical
Oncology
UC San Diego

Pioneering Solution Providers

**BILLION
TO ONE**

BIQIVT
ELEVATING SCIENCE™

biodesix

Burning Rock Dx

CARIS
LIFE SCIENCES

**FOUNDATION
MEDICINE**

GUARDANT

labcorp

natera

Personalis

**PILLAR
BIOSCIENCES**

Predicine

SAGA
DIAGNOSTICS

TEMPUS



Pre-Conference Day

Tuesday, February 3, 2026

 **10** Liquid Biopsy for Precision Oncology Summit

February 3-5, 2026
La Jolla, San Diego, CA

10am-8pm

Kick off your summit experience by registering your interest to join **Personalis**, **Natera** and **Guardant Health** for deep-dive engagers designed to give you an inside look at their latest technologies, how they are being applied across biopharma, and the exciting impact they are already having on the field.

These workshops go beyond standard presentations - they are built to be interactive, practical and directly relevant to your work. You'll gain early access to insights that will shape the discussions across the main conference days, while having the chance to put your own questions directly to the experts driving these advances. **What to expect:**



Expert-led presentations

showcasing cutting-edge tools and data that you could leverage for your pipeline



Interactive roundtable discussions

to share challenges and compare approaches with peers, giving you strategies to overcome bottlenecks for your trial



Thought-provoking panels

bringing together multiple perspectives to tackle key questions head-on

Join these sessions to get ahead of the conversation, deepen your understanding of the technology landscape, and make valuable connections before the main conference begins.

Register your interest to join the Pre-Conference Day Engagers:



Personalis

Join **Personalis** for a deep dive engager into their latest technologies and approaches, and explore how they are shaping the future of precision oncology



natera

Hear from **Natera** as they share insights during this gripping engager, into their newest innovations and real-world applications driving progress in liquid biopsy



GUARDANT

Engage with **Guardant Health** in an interactive engager uncovering cutting-edge solutions and the impact they are having across biopharma and clinical practice

Please note: Attendance at these sessions is subject to availability and partner approval



+1 617 455 4188



info@hansonwade.com



www.lbx-summit.com



Biomarkers & Companion Diagnostics



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Conference Day One

Wednesday, February 4, 2026

 **10th Anniversary**
Liquid Biopsy for Precision Oncology Summit
February 3-5, 2026
La Jolla, San Diego, CA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



7.30 Morning Check-In & Coffee

8.15 Chair's Opening Remarks

Transforming a Decade of Liquid Biopsy Progress into Routine Clinical Impact for Every Patient



Daad Abighanem
Cancer Patient/Survivor
Fight CRC

8.20 **The Real-World Impact of Liquid Biopsy: The Patient Voice**

As we open the 10th Liquid Biopsy for Precision Oncology Summit, we set aside the innovation and technology to begin with the perspective that matters most: the patient voice.



Jon Baden
Executive Director
& Head of Precision
Medicine
Bristol Myers Squibb

8.30 **10 Years of Liquid Biopsy: Igniting a New Era in Precision Oncology**

- Highlighting key scientific, technological, and regulatory milestones that have shaped the past decade of liquid biopsy innovation
- Identifying the most pressing challenges that still hinder broader adoption across trial phases, tumor types, and clinical settings
- Outlining the next strategic priorities needed to ensure liquid biopsies become a standard, validated tool for patient selection, monitoring, and treatment optimization in every clinical trial



FOUNDATION
MEDICINE®

9.00 **Presentation Details to be Announced**



Steffan Ho
Vice President –
Translational Oncology
Pfizer

9.30 **Confronting Complexity: Defining the Next Decade of Liquid Biopsy in Precision Oncology**

- Confronting the translational hurdles that limit liquid biopsy adoption in drug development, from tumor heterogeneity and assay sensitivity to cost and trial feasibility
- Integrating emerging technologies such as methylation profiling and AI with the rigor required for clinical validation in oncology trials
- Defining how pharma decision-making will shape the path from exploratory assays to scalable, routine tools that deliver real patient impact



GUARDANT

10.00 **Presentation Details to be Announced**



10.30 **Morning Break & Speed Networking**

As the liquid biopsy community comes together for the 10th anniversary meeting, this dedicated session is designed to help you build meaningful new connections. All attendees will have the chance to meet peers across pharma, biotech, diagnostics and academia, ensuring valuable relationships that extend beyond the summit.

Standardizing Liquid Biopsies to Drive Reliable, Scalable Adoption Across Trials & Clinical Practice



Lauren Leiman
Executive Director
BLOODPAC



11.30 **Interactive Session: Breaking Down Standardization Barriers Through Consistent Terminology & Metrics to Boost Liquid Biopsy Adoption**

- What are the key roadblocks that continue to hinder standardization across liquid biopsy platforms, assays, and reporting?
- Establishing shared definitions, thresholds, and response criteria to align a fragmented field
- Building a practical roadmap for standardization, including actionable milestones and measurable impact to track progress and build confidence



natera

12.00 **Presentation Details to be Announced**



Conference Day One

Wednesday, February 4, 2026



February 3-5, 2026
La Jolla, San Diego, CA

WELCOME

EXPERT SPEAKERS

12.30 Panel Discussion: Bridging the Gap from Innovation to Access by Aligning Standardization, Policy & Reimbursement for Liquid Biopsy

- Uncovering how inconsistent definitions, metrics, and data standards are hindering payer confidence and policy support for liquid biopsy
- Exploring the role of pre-competitive collaboration in driving standardization to unlock broader reimbursement and clinical adoption
- Identifying immediate policy actions and evidence needs to align stakeholders and accelerate access to serial testing and early detection



Hadly Clark
Director
Faster Cures - Milken Institute



Anthony Chi
Medical Director
Kaiser Permanente



Amrita Pati
Executive Director of Computational Biology, Precision Medicine
Amgen

"TEMPUS

1.00 Presentation Details to be Announced



1.30 Lunch Break & Networking

Track A: Preclinical Development & Early Translational

Track Chair: Amer Mirza, Vice President, Disease Biology & Translational Sciences, **Septerna**

Track B: Clinical Development & Commercialization

Track Chair: Amrita Pati, Executive Director of Computational Biology, Precision Medicine, **Amgen**

Embedding Robust Analytical Validation into Translational Studies to Drive Clinical Success

Driving Clinical Validation to Enhance Decision-Making & Accelerate Diagnostic Approval

2.20 Advancing Precision Oncology through ctDNA Dynamics

- Exploring how ctDNA dynamics, including methylation patterns, can be leveraged to evaluate therapeutic response and inform treatment decisions
- Discussing the translational value of ctDNA analyses in uncovering mechanisms of resistance and guiding precision-oriented therapies
- Highlighting opportunities to integrate ctDNA into routine clinical workflows to better monitor tumor evolution and improve outcomes for patients with hard-to-treat cancer

Hatim Hassain, Professor of Medical Oncology, **UC San Diego**

2.20 Utility of ctDNA for Response Assessment of Solid Tumors Treated with Personalized Cancer Immunotherapy

- Demonstrating how ctDNA identifies molecular response and tracks response duration where MRI-based RECIST lacks clarity
- Leveraging ctDNA alongside imaging to enable earlier and more accurate detection of therapeutic benefit in second-line advanced HCC
- Using ctDNA-guided monitoring as an exploratory endpoint to inform trial design, optimize treatment strategies, and lay the groundwork for broader regulatory acceptance

Ildiko Csiki, Chief Medical Officer, **Geneos Therapeutics**

2.45 Presentation Details to be Announced



2.45 Presentation Details to be Announced



AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



+1 617 455 4188 @ info@hansonwade.com

www.lbx-summit.com Biomarkers & Companion Diagnostics



Conference Day One

Wednesday, February 4, 2026



February 3-5, 2026
La Jolla, San Diego, CA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

3.15 Fireside Chat: Overcoming Sensitivity & Specificity Challenges to Deliver Reliable Liquid Biopsy Results at Scale

- Defining and achieving the optimal analytical thresholds for sensitivity and specificity in line with intended clinical use – how sensitive is too sensitive?
- Discussing strategies to minimize CHIP related false positives and false negatives without compromising turnaround time or trial feasibility
- Refining analytical validation data strategies to support regulatory submissions, companion diagnostic partnerships, and confident clinical decision-making

Hua Gong, Vice President, Translational Science, **BBOT (BridgeBio Oncology Therapeutics)**

Joan Chen, Executive Director, Bioinformatics, **Boundless Bio**

3.15 Panel Discussion: Clinically Validating Liquid Biopsies for Early Clinical Endpoints to Enhance Patient Selection & Monitoring

- What evidence and study designs are most critical to clinically validate liquid biopsies as early endpoints in trials, and how do these differ across indications?
- How can validated liquid biopsy endpoints improve patient selection and ongoing monitoring to accelerate therapeutic development and decision-making?
- What regulatory, operational, and data-standardization challenges still need to be addressed to ensure liquid biopsy endpoints are trusted and broadly adopted?

Zoe June Assaf, Senior Director, Cancer Genomics & Emerging Technologies, **Revolution Medicines**

Ildiko Csiki, Chief Medical Officer, **Geneos Therapeutics**

Partha Das, Global Medical Director - Precision Medicine, **Johnson & Johnson**

3.45 Presentation Details to be Announced



3.45 Presentation Details to be Announced



4.15 Afternoon Networking Break

Harnessing Novel AI, Methylation & Cutting-Edge Technology to Unlock Unprecedented Liquid Biopsy Insights

5.15 Leveraging Mutation & Methylation-Based ctDNA Profiling to Capture Tumor Heterogeneity & Enhance Clinical Readouts

- Demonstrating how broader ctDNA panels extend beyond single-gene tracking in advanced cancer, as a surrogate readout of clinical efficacy and to reveal tumor heterogeneity and evolving drivers of resistance
- Lessons from applying methylation-based sequencing approaches in oncology trials, including challenges in data interpretation and reporting
- Opportunities and limitations of integrating fragmentomics insights derived from methylation data to complement response monitoring in advanced disease

Anneleen Daeman, Executive Director of Translational Medicine, **ORIC Pharmaceuticals**

Seamlessly Integrating Liquid Biopsies into Clinical Trials to Streamline Multi-Vendor & Operational Barriers

5.15 Building Standardized ctDNA & MRD Strategies to Accelerate Clinical Development of Immune-Based Therapies

- Examining how ctDNA and MRD assays can serve as regulatory-acceptable biomarkers and support commercialization of CAR-T and T-cell engager therapies
- Addressing harmonization challenges across assay platforms and how standardization can streamline late-phase trials and companion diagnostic development
- Exploring opportunities for integrated, multi-omic blood-based assays to provide scalable solutions that meet payer, regulatory, and clinician expectations

Cedric Dos Santos, Global Product Leader, **AstraZeneca**



Conference Day One

Wednesday, February 4, 2026



February 3-5, 2026
La Jolla, San Diego, CA

5.40 Underpinning the Value of Urine for Predictive & Monitoring Biomarkers in Bladder Cancer

- Comparing utDNA with traditional ctDNA for monitoring disease burden and detecting recurrence
- Optimizing assay sensitivity, specificity & turnaround time for real-world clinical use
- Leveraging longitudinal utDNA analysis to guide treatment decisions and improve patient outcomes

David Weingeist, Scientific Director, Oncology Diagnostics
Leader, **Johnson & Johnson**

5.40 Liquid Biopsy Across the Drug Lifecycle: Discovery, Differentiation & Adoption

- Showing how Amgen leverages ctDNA and other modalities across discovery, clinical development, and commercialization to accelerate differentiation, regulatory approvals, and market adoption
- Highlighting case studies where ctDNA and liquid biopsy analyses informed dose selection, early efficacy readouts, and patient stratification, directly supporting faster decision-making and clinical success
- Discussing how Amgen generates the biomarker evidence base needed for regulators, payers, and clinicians to embrace liquid biopsy as a standard tool in advancing precision medicine

Amrita Pati, Executive Director of Computational Biology,
Precision Medicine, Bioinformatics, **Amgen**



6.05 Drinks Reception, Hosted by Foundation Medicine



**FOUNDATION
MEDICINE**

7.05 Evening Engager, Hosted by Foundation Medicine

This exclusive session offers pharma leaders a unique opportunity to engage directly with Foundation Medicine and each other in a focused networking environment. Building on the day's discussions, the engager will spark conversation on the evolving role of liquid biopsy in oncology and provide a platform to explore future partnerships, collaborations and strategic priorities.

Please note: Attendance at this session is subject to availability and partner approval

■ An excellent conference. It was a good mix of topics broadly relevant to the community covered in plenary sessions, more specialized options in two parallel tracks, and easy access to exhibitors ■

Past Speaker, Executive Director – Translational Medicine,
Oric Pharmaceuticals



Conference Day Two

Thursday, February 5, 2026

 **Liquid Biopsy for
Precision Oncology Summit**
February 3-5, 2026
La Jolla, San Diego, CA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



8.00 Morning Check-In & Coffee

8.20 Chair's Opening Remarks

Ensuring MRD Clears Regulatory, Data & Adoption Hurdles to Become a Widely Accepted Surrogate Endpoint in Clinical Trials

8.30 **Translating MRD into Regulatory Evidence: Defining the Approval & Adoption Pathway in Solid Tumors**



Claudia Dollins
Vice President,
Regulatory Affairs
GSK

- Addressing analytical and clinical validation standards required to support regulatory review of MRD assays in oncology drug development
- Integrating MRD into trial design to generate evidence packages that enable regulatory qualification as surrogate endpoints
- Aligning regulatory and payer expectations to accelerate acceptance of MRD as a decision-making tool in routine oncology practice



9.00 **Presentation Details to be Announced**

9.30 **Panel Discussion: Accelerating the Use of MRD as a Surrogate Endpoint Across Indications**

- Leveraging existing MRD evidence from hematology (e.g. multiple myeloma) to inform regulatory and policy pathways in new settings
- Driving alignment on assays, thresholds, endpoints, and timepoints to ensure cross-study comparability and reproducibility
- Building collaborative frameworks and secure data-sharing models to generate the robust evidence required by regulators and payers



Jennifer Hamilton
Vice President,
Precision Medicine
Regeneron



Cedric Dos Santos
Global Product Leader
AstraZeneca



Fernando Cruz-Guilloty
Director - Oncology Precision
Medicine & Lung Franchise Lead
Johnson & Johnson



10.30 Morning Refreshments & Networking Break

Great presentations, lots of networking - keeping up with the latest advancements and seeing new Dx partners

Past Attendee, Director of CDx, **AbbVie**

Conference Day Two

Thursday, February 5, 2026

 **Liquid Biopsy for Precision Oncology Summit**
February 3-5, 2026
La Jolla, San Diego, CA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Track A: Preclinical Development & Early Translational

Track B: Clinical Development & Commercialization

From Exploratory Tools to Accepted Endpoints: Unlocking the Path for ctDNA & MRD in Solid Tumors

Navigating Regulatory & Policy Hurdles to Accelerate Global Adoption of Liquid Biopsies

11.30 The Evolution of The ctDNA Assays – From Initial Clinical & Regulatory Utility to a Potential Innovative MRD Endpoint in Solid Tumor Indications

- Clinical and regulatory utility of first generation ctDNA assays
- The need for innovative endpoints and important advancements of ctDNA assays to serve as MRD assays
- An example of a potential pathway to establish ctDNA for MRD testing in a solid tumor indication

Oliver Rosen, Chief Medical Officer, **Akamis Bio**

11.30 Navigating the Complex, Uncertain Regulatory Environment to Expedite Global Patient Access to Liquid Biopsy Testing

- How to drive global approvals – and expedited approvals – for liquid biopsies
- Understanding evolving global regulatory landscape and call for harmonization
- Emphasizing the importance of early regulatory considerations in clinical studies

Michelle Neff, Associate Vice President, Global Regulatory Affairs, Diagnostics & Companion Diagnostics, **Eli Lilly**

11.55 From Assay to Action – Making MRD a Practical Tool for Treatment Decisions in Hematology

- Bridging assay development and translational research to define clinically meaningful MRD cutoffs and endpoints
- Designing MRD-guided clinical trials to inform treatment decisions, including escalation, consolidation & de-escalation strategies
- Addressing turnaround time, cost and implementation challenges to ensure MRD assays can move from trials into routine practice

Yanwen Jiang, Distinguished Scientist, **Genentech**

11.55 Roundtable Discussion: Designing Clinical Trials with MRD as a Patient Identification Tool to Transform Precision Oncology

- What are the biggest opportunities and limitations of leveraging MRD as a patient identification tool compared with its use for monitoring or as a trial endpoint?
- How are pharma and biotech teams approaching assay selection given variability in MRD sensitivity and methodologies?
- What practical challenges – regulatory, operational, or clinical – remain for embedding MRD-driven patient identification into trial design at scale?



12.20 Presentation Details to be Announced



12.20 Session Available for Partnership

Inquire to Learn More



12.30 Lunch Break & Networking



Conference Day Two

Thursday, February 5, 2026

Unlocking the Potential of CTCs, Extracellular Vesicles, miRNAs & Proteins to Transform Clinical Decision Making

Advancing Reimbursement, Access & Adoption to Deliver Liquid Biopsies to Every Patient in Need

1.30 RNA Liquid Biopsy Technology for Precision Oncology

- Utilizing nanopore sequencing to discover over 250,000 novel RNA biomarkers of precancer and cancer
- Training machine learning models using novel RNA features to classify precancer and cancer with near perfect sensitivity and specificity
- Discovering novel therapeutic targets and RNA biomarkers for precision oncology

Daniel Kim, Assistant Professor & Co-Chair, **UC Santa Cruz & NIH Liquid Biopsy Scientific Interest Group**

1.30 Tackling Policy Issues to Ensure Patient Access to Testing & Facilitate Longitudinal Monitoring

- Assessing the limitations of the current policy environment for liquid biopsies, especially for serial monitoring
- How to influence and overcome policy issues preventing patient access to therapeutics
- What are the realistic milestones to hit to expedite better patient access to better drug-diagnostics?

Hadly Clark, Director, **Faster Cures, Milken Institute**

1.55 Presentation Details to be Announced



1.55 Presentation Details to be Announced



2.25 Expanding the Role of Emerging Analytes in Liquid Biopsy to Strengthen Translational Oncology Studies

- Exploring how protein, RNA and DNA in circulation can provide value in early-phase solid tumor studies
- Assessing the unique opportunities and limitations of protein-based analysis compared with nucleic acids
- How exploratory analytes can complement DNA-based approaches to support ADC development and broader translational insights


Jelveh Lameh, Head, Translational Research, **Zai Lab**

2.25 Empowering Clinicians to Confidently Integrate Liquid Biopsies into Everyday Practice

- Addressing knowledge gaps by providing clear, accessible education on interpreting LBx results and linking them to treatment decisions
- Collaborating with medical societies to embed LBx guidance into specialty guidelines and continuing medical education programs
- Building trusted, ongoing communication channels between diagnostics developers, pharma, and front-line clinicians

Anjee Davis, Chief Executive Officer, **FightCRC**

2.50 Presentation Details to be Announced



2.50 Presentation Details to be Announced



3.20 Afternoon Networking Break

Conference Day Two

Thursday, February 5, 2026

 **Liquid Biopsy for
Precision Oncology Summit**
February 3-5, 2026
La Jolla, San Diego, CA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

New Frontiers: Charting the Next Era of Liquid Biopsies to Transform Medicine Beyond Cancer



Cynthia Sandoval
Senior Director,
Clinical Biomarker
Development
Eli Lilly

3.50 New Frontiers in Plasma-Based Diagnostics for Alzheimer's Evaluation

- **Advancements in Alzheimer's Diagnostics:** The presentation explores the multi-step process of diagnosing Alzheimer's Disease (AD), emphasizing the role of various clinicians and the use of CSF testing and PET neuroimaging, and the overall importance of biomarkers in evaluating AD pathology
- **Biomarker Innovations and Applications:** The presentation delves into the progress towards a biological definition of AD, categorizing biomarkers into amyloid plaques, tau, and neurodegeneration. It discusses the emerging use of blood-based biomarkers (BBMs) for evaluating AD pathology, including their advantages, challenges, and the need for standardization in plasma biomarker testing
- **Future Directions and Recommendations:** The presentation outlines the rationale for focusing on specific plasma markers like P-tau217, the performance recommendations for BBMs, and the dual cut-point approach to achieve high sensitivity and specificity. It also presents data on commercially available plasma P-tau217 tests and recent updates to guidelines



Leandro Grimaldi
Senior Director,
Head of Strategy &
Operations, Precision
Medicine
Amgen

4.20 Rethinking Strategy: Moving Beyond Disease Stage with AI-Enabled Translational & Retrospective Drug Development

- **Challenge traditional disease stage-focused development** by adopting strategies that transcend indication silos
- **Explore how AI can act as a disruptive enabler** to reimagine how translational data is collected, integrated, and applied
- **Demonstrate how these combined approaches can retrospectively inform new molecule design** and accelerate the next generation of therapies

4.50 Chair's Closing Remarks & End of Conference

“The speaker presentations were excellent, and the selection was comprehensive and very current. The blend of regulatory sciences and relevant scientific innovation was unique and provided one of them best holistic experiences I've had in attending an industry conference”

Past Attendee, Senior Manager of Digital Innovation, **Pfizer**



2026 Partners


10th Liquid Biopsy for Precision Oncology Summit

February 3-5, 2026
La Jolla, San Diego, CA


Expertise Partners



Program Partners



Spotlight Partner



Exhibition Partner



Get Involved



Sam Sarwar

Senior Commercial Director

+1 617 455 4188

sponsor@hansonwade.com

Lead the Charge – Drive Liquid Biopsy Innovation

10th Liquid Biopsy for Precision Oncology Summit

February 3-5, 2026
La Jolla, San Diego, CA

Your Global Platform to Foster New & Existing Relationships within the Rapidly Growing Liquid Biopsy Space

With major collaborations, regulatory milestones, and acquisitions fuelling momentum, investment and partnerships in liquid biopsy are surging. The field is at a critical moment on the path to routine clinical adoption - making now the time to step forward as a strategic partner and thought leader.

As the leading summit exclusively focused on liquid biopsy in oncology drug development, this meeting offers a unique platform for senior industry leaders to engage directly with the top experts advancing the field. Attendees come with a clear mandate: seeking cutting-edge assays, analytes, technologies, and applications to accelerate clinical development, regulatory approval, and commercialization. This is your opportunity to showcase solutions that directly meet those needs and position your company as essential to progress.

Join 15+ leading diagnostic vendors already confirmed and demonstrate to a packed room of 250+ precision medicine decision-makers why your company should be their next key partner.



Unlock New Connections

Meet senior pharma and biotech leaders looking for liquid biopsy partners to solve trial, regulatory and adoption challenges, ensuring you are on their radar



Showcase Innovation

Lead panels, host workshops or present case studies on ctDNA, MRD, methylation, fragmentomics and AI to an audience of expert decision makers who need your insights for their trials



Guide Pharma's Strategy


Align with Pfizer, Amgen, AstraZeneca, BMS, Regeneron, GSK, Genentech and Eli Lilly at the center of biopharma decision-making, directly proving your expertise and value



Gain Insider Intelligence

Hear directly from KOLs on standardization, reimbursement, MRD acceptance and emerging analytes beyond oncology - and hear from competitors on what they are prioritizing

Seniority of Attendees




C-Level: 15%

VP / Head: 25%

Director: 45%

Scientist: 15%

Type of Companies Attending



*Statistics taken from the 9th Liquid Biopsy for Precision Oncology Summit

Get Involved



Sam Sarwar

Senior Commercial Director

+1 617 455 4188

sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

 www.lbx-summit.com/register

 Tel: +1 617 455 4188

 Email: info@hansonwade.com



Don't Get Left Behind – hear first-hand how the world's leading pharmaceutical, biotech, and diagnostic companies are setting the new standard for liquid biopsy in drug development



Be in the Room Where Decisions are Made – uncover strategies for validation, regulation, and commercialization that will shape the future of precision oncology



Connect With Everyone Who Matters – 250+ senior leaders across pharma, diagnostics, payers, and regulators you simply can't afford to miss

All prices shown in USD. Please visit the website for full pricing options or email info@hansonwade.com

Drug Developers & Research Institutes**

Conference + Engagers	FREE*
Conference Only	FREE*

Registration is FREE* if you work for a drug developer, research organisation, or academic institution.

*Please note that credit card details will be taken upon registration, and a nominal fee of \$0.50 charged. This amount is fully refundable at the end of the month in which the event takes place, provided you attend the event.

**A drug developer, researcher or academic must have a pipeline candidate and/or work for an academic institution, and must not provide solutions or services for a fee to any other company.

Free access is only granted once approval of eligibility is confirmed. Hanson Wade retain the right to reject or cancel your registration if eligibility criteria are not met, and paid registration will then be required to access the event.

Hanson Wade reserves the right to charge free access guests a non-refundable charge of \$100 if they do not attend the entire event if they fail to give 7 working days' notice of non-attendance

Vendors & Solution Providers***	Early Bird Pricing: Book by Friday, December 12	On the Door Pricing
Conference Only	\$3,499 (save \$500)	\$3,999

***Service and Solution Providers refer to all employees from Consultancies, CRO, Software, R&D, Diagnostic, or Pre-Clinical Service Provider organisations who partner with, or provide services to, drug developers and/or research organisations.


Team Discounts***

- 10% discount – 3 Attendees
- 15% discount – 4 Attendees
- 20% discount – 5+ Attendees

***Please note that discounts are only valid on paid passes when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: info@hansonwade.com



Venue

San Diego Marriot La Jolla
4240 La Jolla Village Dr, La Jolla, CA 92037, United States
www.marriott.com/en-us/hotels/sanlj-san-diego-marriott-la-jolla/own/

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom

